Affiliation:
1. Department of Pharmacy University of California, Davis Medical Center Sacramento California USA
2. Department of Pharmacy University of North Carolina Medical Center Chapel Hill North Carolina USA
3. Department of Pharmacy University of Kentucky HealthCare Lexington Kentucky USA
4. Department of Pharmacy University of Wisconsin Hospitals and Clinics Madison Wisconsin USA
5. Heart Failure Section Minneapolis Heart Institute at Abbot Northwestern Hospital Minneapolis Minnesota USA
Abstract
AbstractSince its first success in 1975, extracorporeal membrane oxygenation (ECMO) has been used with increasing frequency for pulmonary and cardiopulmonary bypass. Use in adults has increased exponentially since the early 2000s, but despite thousands of international cannulations using both veno‐arterial (VA) and veno‐venous (VV) ECMO, there are still significant hemocompatibility‐related adverse events. Current management of anticoagulation has been based on the Extracorporeal Life Support Organization guidance published in 2014 with recent updates published in 2022. Despite this guidance, there is still limited international consensus on how to manage anticoagulation in ECMO. For this review, we completed a comprehensive search of multiple electronic databases to identify studies pertaining to anticoagulation of adult patients on VV or VA‐ECMO. The highest priority was given to sources that were prospective, randomized, controlled studies, but in the absence of such resources, observational studies, retrospective uncontrolled studies, and case series/reports were considered for inclusion. This document serves to provide a comprehensive review of the current understanding of management pertaining to anticoagulation relating to ECMO.